Skip to main content

Table 3 Change from baseline over time in Medical Outcome Study Short Form 36 (SF-36) domain scores

From: The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials

SF-36 Domain Treatment Group Week 8 Week 16 Week 26 End Point
Physical Functioning Placebo 3.2 ± 0.8 3.2 ± 0.9 5.0 ± 1.0 3.6 ± 0.9
  Topiramate 4.8 ± 0.8 6.4 ± 0.9 8.3 ± 1.0 5.3 ± 0.8
   NS p = 0.025 p = 0.023 NS
Bodily Pain Placebo 6.2 ± 1.2 6.7 ± 1.3 6.7 ± 1.4 4.6 ± 1.2
  Topiramate 12.0 ± 1.1 14.3 ± 1.4 14.5 ± 1.4 11.5 ± 1.2
   p < 0.001 p < 0.001 p < 0.001 p < 0.001
Vitality Placebo 1.9 ± 1.0 3.1 ± 1.0 3.9 ± 1.2 1.8 ± 1.0
  Topiramate 3.8 ± 1.0 7.9 ± 1.1 10.1 ± 1.2 5.2 ± 1.0
   NS p = 0.008 p < 0.001 p = 0.035
General Health Placebo 1.0 ± 0.7 0.4 ± 0.8 1.6 ± 0.9 0.8 ± 0.8
  Topiramate 3.4 ± 0.7 4.3 ± 0.9 4.5 ± 0.9 2.2 ± 0.8
   p = 0.009 p < 0.001 p = 0.027 NS
Role- Emotional Placebo 4.5 ± 2.0 4.1 ± 2.1 6.5 ± 2.3 3.0 ± 2.0
  Topiramate 2.2 ± 2.0 8.0 ± 2.2 9.3 ± 2.3 2.3 ± 2.0
   NS NS NS NS
Role- Physical Placebo 14.4 ± 2.2 15.0 ± 2.2 15.9 ± 2.5 12.0 ± 2.1
  Topiramate 19.3 ± 2.2 26.6 ± 2.4 24.1 ± 2.5 17.9 ± 2.1
   NS p < 0.001 p = 0.018 NS
Mental Health Placebo -0.2 ± 0.9 0.8 ± 0.8 0.6 ± 1.0 -0.2 ± 0.9
  Topiramate -1.5 ± 0.9 2.9 ± 0.9 3.2 ± 1.0 -0.5 ± 0.9
   NS NS p = 0.034 NS
Social Functioning Placebo 5.3 ± 1.2 7.8 ± 1.2 6.8 ± 1.3 4.8 ± 1.2
  Topiramate 4.8 ± 1.2 8.5 ± 1.3 10.8 ± 1.3 4.8 ± 1.2
   NS NS p = 0.010 NS
Physical Component Summary Placebo 2.8 ± 0.4 2.8 ± 0.4 3.2 ± 0.5 2.5 ± 0.4
  Topiramate 5.1 ± 0.4 5.7 ± 0.5 5.7 ± 0.5 4.7 ± 0.4
   p < 0.001 p < 0.001 p < 0.001 p < 0.001
Mental Component Summary Placebo 0.3 ± 0.6 0.8 ± 0.5 0.9 ± 0.6 0.1 ± 0.5
  Topiramate -0.6 ± 0.6 1.5 ± 0.6 2.2 ± 0.6 -0.2 ± 0.5
   NS NS p = 0.043 NS